Amgen Q4 2025 revenue rises 9% to $9.9 billion; 2026 guidance set at $37.0-38.4 billion

Amgen reported fourth-quarter 2025 total revenue of $9.9 billion, up 9%, and non-GAAP EPS of $5.29. For full-year 2025 revenue rose 10% to $36.8 billion and non-GAAP EPS reached $21.84. The company guided 2026 total revenue to $37.0-38.4 billion and non-GAAP EPS to $21.60-23.00, and it expects Repatha's net selling price to fall by roughly mid-single digits this year.

• Q4 2025 total revenues $9.9 billion, up 9%; GAAP EPS $2.45
• Q4 2025 non-GAAP EPS $5.29
• Full-year 2025 revenues $36.8 billion, up 10%; non-GAAP EPS $21.84
• 2026 guidance: total revenues $37.0-38.4 billion; non-GAAP EPS $21.60-23.00; GAAP EPS $15.45-16.94
• Repatha net selling price expected to decline by roughly mid-single digits in 2026

SEC filing 8-K · accession 0000318154-26-000003 · sec.gov ↗